Recent Posts
- Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
- Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
- Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
- Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
- Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Recent Comments
No comments to show.